Asceneuron SA

Asceneuron is looking to rival Eli Lilly and Biogen in a new class of oral drugs which block the build-up of toxic tau in Alzheimer’s disease, and has raised $100m to further its plans. The overs

Without adequate treatments, neurodegenerative diseases such as Alzheimer’s and Parkinson’s remain an important unmet medical burden for aging societies. In a discussion at the 2019 Biotech Showcase,

Pharma and biotech drug developers have been targeting disorders affecting the central nervous system for decades but many conditions still have no effective treatments that target the root cause of d

Promethera Biosciences SA NV has appointed Henrik L. Luessen chief business officer (CBO), Nancy Veulemans vice president clinical & medical affairs and Decebal Bora vice president regul